Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
48
PLX Quote, Financials, Valuation and Earnings
Last price:
$2.89
Seasonality move
:
9.71%
Day range:
$2.88 - $3.01
52-week range:
$1.32 - $3.19
Dividend yield:
0%
P/E ratio:
41.44x
P/S ratio:
3.66x
P/B ratio:
4.38x
Volume:
1.5M
Avg. volume:
1.5M
1-year change:
23.61%
Market cap:
$231.6M
Revenue:
$53.4M
EPS (TTM):
$0.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PLX
Protalix Biotherapeutics, Inc.
|
$14.2M | -- | 84.91% | -- | $11.00 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
CRIS
Curis, Inc.
|
$3.2M | -$0.43 | -2.86% | -65.51% | $14.00 |
|
DNLI
Denali Therapeutics, Inc.
|
$2.7M | -$0.76 | 559.6% | -2.21% | $32.86 |
|
NEPH
Nephros, Inc.
|
$4.5M | $0.01 | 15.01% | -69.79% | $6.50 |
|
OSUR
OraSure Technologies, Inc.
|
$26.4M | -$0.15 | -7.72% | -29.73% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PLX
Protalix Biotherapeutics, Inc.
|
$2.88 | $11.00 | $231.6M | 41.44x | $0.00 | 0% | 3.66x |
|
AGEN
Agenus, Inc.
|
$3.33 | $12.33 | $120.4M | -- | $0.00 | 0% | 0.84x |
|
CRIS
Curis, Inc.
|
$1.14 | $14.00 | $14.7M | -- | $0.00 | 0% | 1.09x |
|
DNLI
Denali Therapeutics, Inc.
|
$21.18 | $32.86 | $3.3B | -- | $0.00 | 0% | 6.62x |
|
NEPH
Nephros, Inc.
|
$3.91 | $6.50 | $41.6M | 28.31x | $0.00 | 0% | 2.35x |
|
OSUR
OraSure Technologies, Inc.
|
$3.15 | $6.00 | $226M | 26.67x | $0.00 | 0% | 2.01x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -2.030 | 4.58% | 2.00x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
CRIS
Curis, Inc.
|
192.35% | 2.868 | 144.76% | 0.62x |
|
DNLI
Denali Therapeutics, Inc.
|
4.58% | 0.777 | 2.09% | 9.43x |
|
NEPH
Nephros, Inc.
|
10.34% | 3.145 | 2.3% | 3.17x |
|
OSUR
OraSure Technologies, Inc.
|
-- | 0.712 | -- | 5.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
DNLI
Denali Therapeutics, Inc.
|
-$2.9M | -$137.4M | -42.48% | -44.34% | -- | -$105.9M |
|
NEPH
Nephros, Inc.
|
$2.9M | $314K | 14.16% | 16.22% | 6.59% | $99K |
|
OSUR
OraSure Technologies, Inc.
|
$11M | -$16.9M | -17.66% | -18.18% | -62.97% | -$9.9M |
Protalix Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns PLX or AGEN?
Agenus, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of -116.82%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About PLX or AGEN?
Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 281.94%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 270.37%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Agenus, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Agenus, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PLXProtalix Biotherapeutics, Inc.1 0 0 AGENAgenus, Inc.2 1 0 -
Is PLX or AGEN More Risky?
Protalix Biotherapeutics, Inc. has a beta of -0.206, which suggesting that the stock is 120.633% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock PLX or AGEN?
Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PLX or AGEN?
Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Protalix Biotherapeutics, Inc.'s net income of $2.4M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 41.44x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 3.66x versus 0.84x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PLXProtalix Biotherapeutics, Inc.3.66x 41.44x $17.9M $2.4M AGENAgenus, Inc.0.84x -- $30.2M $63.9M
-
Which has Higher Returns PLX or CRIS?
Curis, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of -243.36%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About PLX or CRIS?
Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 281.94%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1128.07%. Given that Curis, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe Curis, Inc. is more attractive than Protalix Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PLXProtalix Biotherapeutics, Inc.1 0 0 CRISCuris, Inc.4 0 0 -
Is PLX or CRIS More Risky?
Protalix Biotherapeutics, Inc. has a beta of -0.206, which suggesting that the stock is 120.633% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.
-
Which is a Better Dividend Stock PLX or CRIS?
Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PLX or CRIS?
Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are larger than Curis, Inc. quarterly revenues of $3.2M. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than Curis, Inc.'s net income of -$7.7M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 41.44x while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 3.66x versus 1.09x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PLXProtalix Biotherapeutics, Inc.3.66x 41.44x $17.9M $2.4M CRISCuris, Inc.1.09x -- $3.2M -$7.7M
-
Which has Higher Returns PLX or DNLI?
Denali Therapeutics, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of --. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat Denali Therapeutics, Inc.'s return on equity of -44.34%.
Company Gross Margin Earnings Per Share Invested Capital PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M -
What do Analysts Say About PLX or DNLI?
Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 281.94%. On the other hand Denali Therapeutics, Inc. has an analysts' consensus of $32.86 which suggests that it could grow by 55.13%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Denali Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Denali Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PLXProtalix Biotherapeutics, Inc.1 0 0 DNLIDenali Therapeutics, Inc.17 1 0 -
Is PLX or DNLI More Risky?
Protalix Biotherapeutics, Inc. has a beta of -0.206, which suggesting that the stock is 120.633% less volatile than S&P 500. In comparison Denali Therapeutics, Inc. has a beta of 1.023, suggesting its more volatile than the S&P 500 by 2.256%.
-
Which is a Better Dividend Stock PLX or DNLI?
Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Denali Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. Denali Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PLX or DNLI?
Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are larger than Denali Therapeutics, Inc. quarterly revenues of --. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than Denali Therapeutics, Inc.'s net income of -$126.9M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 41.44x while Denali Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 3.66x versus 6.62x for Denali Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PLXProtalix Biotherapeutics, Inc.3.66x 41.44x $17.9M $2.4M DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M
-
Which has Higher Returns PLX or NEPH?
Nephros, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of 7.07%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat Nephros, Inc.'s return on equity of 16.22%.
Company Gross Margin Earnings Per Share Invested Capital PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M NEPHNephros, Inc.60.47% $0.03 $11.2M -
What do Analysts Say About PLX or NEPH?
Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 281.94%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 66.24%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Nephros, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Nephros, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PLXProtalix Biotherapeutics, Inc.1 0 0 NEPHNephros, Inc.1 0 0 -
Is PLX or NEPH More Risky?
Protalix Biotherapeutics, Inc. has a beta of -0.206, which suggesting that the stock is 120.633% less volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.397, suggesting its more volatile than the S&P 500 by 39.715%.
-
Which is a Better Dividend Stock PLX or NEPH?
Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PLX or NEPH?
Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are larger than Nephros, Inc. quarterly revenues of $4.8M. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than Nephros, Inc.'s net income of $337K. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 41.44x while Nephros, Inc.'s PE ratio is 28.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 3.66x versus 2.35x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PLXProtalix Biotherapeutics, Inc.3.66x 41.44x $17.9M $2.4M NEPHNephros, Inc.2.35x 28.31x $4.8M $337K
-
Which has Higher Returns PLX or OSUR?
OraSure Technologies, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of -72.06%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat OraSure Technologies, Inc.'s return on equity of -18.18%.
Company Gross Margin Earnings Per Share Invested Capital PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M OSUROraSure Technologies, Inc.40.98% -$0.27 $340.8M -
What do Analysts Say About PLX or OSUR?
Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 281.94%. On the other hand OraSure Technologies, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 90.48%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than OraSure Technologies, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than OraSure Technologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PLXProtalix Biotherapeutics, Inc.1 0 0 OSUROraSure Technologies, Inc.1 2 0 -
Is PLX or OSUR More Risky?
Protalix Biotherapeutics, Inc. has a beta of -0.206, which suggesting that the stock is 120.633% less volatile than S&P 500. In comparison OraSure Technologies, Inc. has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.058%.
-
Which is a Better Dividend Stock PLX or OSUR?
Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OraSure Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. OraSure Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PLX or OSUR?
Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are smaller than OraSure Technologies, Inc. quarterly revenues of $26.8M. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than OraSure Technologies, Inc.'s net income of -$19.3M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 41.44x while OraSure Technologies, Inc.'s PE ratio is 26.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 3.66x versus 2.01x for OraSure Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PLXProtalix Biotherapeutics, Inc.3.66x 41.44x $17.9M $2.4M OSUROraSure Technologies, Inc.2.01x 26.67x $26.8M -$19.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Sell
36
WLDN alert for Feb 28
Willdan Group, Inc. [WLDN] is down 25.56% over the past day.
